The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / DADA2 Research Reveals Mechanisms & Possible Gene Therapy

DADA2 Research Reveals Mechanisms & Possible Gene Therapy

February 18, 2018 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Festa / SHUTTERSTOCK.COM

Festa / SHUTTERSTOCK.COM

SAN DIEGO—An increasing number of patients is being identified with deficiency of adenosine deaminase type 2 (DADA2); fortunately, researchers and clinicians continue to better understand the genetic disease as well, experts said in a session at the 2017 ACR/ARHP Annual Meeting Nov. 3–8.

You Might Also Like
  • DADA2: A New Disease for Rheumatologists to Understand
  • ADA2 Mutation Connects Vascular Pathology to Immunodeficiency
  • Gene Therapy for OA
Explore This Issue
February 2018
Also By This Author
  • The ACR’s State-of-the-Art Clinical Symposium: Rheumatic, Malignant Disease Mimics Call for Diligence from Rheumatologists

The childhood-onset disease involves loss-of-function mutations to the CECR1 gene (i.e., cat eye syndrome critical region candidate 1), which encodes the enzyme adenosine deaminase 2 (ADA2), the growth factor-like function of which seems to play the biggest role in the disease. Symptoms include fevers, early onset of strokes, vasculitis and livedo racemosa. Cat eye syndrome is not the same as DADA2.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Paul Brogan, MBChB, PhD, professor of rheumatology at University College London (UCL) in London, England, described a disease that doesn’t fit neatly into a box. It gives rise to autoinflammatory features, autoimmune features and immunodeficiency. Autoinflammation and vasculitis arises because monocytes have impaired differentiation toward anti-inflammatory M2 macrophages and skew toward the pro-inflammatory M1 variety. And, there’s an upregulation of neutrophil-related genes. The disease also involves an immuno­deficiency aspect, with reduced memory B cells and increased B cell mortality.

The differential diagnosis is wide ranging, spanning any type of sporadic vascu­litis, other monogenic autoinflammatory diseases such as STING-associated vas­culopathy with onset in infancy (SAVI) and chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE), immunodeficiency, marrow failure and Castleman’s disease.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Clinicians should consider screening for DADA2 in cases of early-onset poly­arteritis nodosa (PAN), familial PAN, PAN with cutaneous and neurological involvement or when PAN resists conventional therapy, Dr. Brogan said.

There have been no formal trials yet for DADA2 treatment, Dr. Brogan said. Doctors use corticosteroids in virtually all patients, but he says it’s not a good long-term option.

“There’s a growing consensus that anti-TNF is the preferred treatment for auto-inflammation vasculitis,” he said. “But in whom and when to start the treatment, particularly for patients who have minimal symptoms, remain controversial and a point for discussion.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Allogeneic hematopoietic stem cell transplantation has produced encouraging results. Researchers reported results last year from 14 patients who’d had bone marrow dysfunction or immunodeficiency in the United States and five European countries. At a median of 18 months of follow-up (ranging from five months to 13 years), all of the patients remained alive and doing well, with no new vascular events, and resolution of their marrow failure and immunodeficiency.1

But Dr. Brogan pointed out the potential problems of post-transplant hematological autoimmunity, acute graft vs. host disease and other complications. And in his lab, work is afoot to develop gene therapy for the disease, he said. At least on a theoretical basis, he said, “… it should be possible. This is a recessive monogenic disease. And that correction for a single gene should restore the ADA2 enzyme activity and cure the problem.”

Pages: 1 2 3 | Single Page

Filed Under: Meeting Reports, Research Reviews, Vasculitis Tagged With: ACR/ARHP Annual Meeting, adenosine deaminase 2, DADA2, gene therapy, genetic diseaseIssue: February 2018

You Might Also Like:
  • DADA2: A New Disease for Rheumatologists to Understand
  • ADA2 Mutation Connects Vascular Pathology to Immunodeficiency
  • Gene Therapy for OA
  • Research Reveals Clues Into Inflammatory Process of Crystal Arthropathies Note Experts at the 2013 ACR/ARHP Annual Meeting

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)